• Je něco špatně v tomto záznamu ?

Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network

P. Hellamand, MGH. van de Sande, LM. Ørnbjerg, T. Klausch, KK. Eklund, H. Relas, MJ. Santos, E. Vieira-Sousa, AG. Loft, B. Glintborg, M. Østergaard, U. Lindström, JK. Wallman, B. Michelsen, KM. Fagerli, I. Castrejón, B. Gudbjornsson, TJ. Love, J....

. 2024 ; 76 (4) : 587-598. [pub] 20240225

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006622

Grantová podpora
European Spondyloarthritis Research Collaboration Network
Novartis

OBJECTIVE: Women with psoriatic arthritis (PsA) may have reduced tumor necrosis factor inhibitor (TNFi) effectiveness compared to men. We examined sex differences in treatment response and retention rates during 24 months of follow-up among patients with PsA initiating their first TNFi. METHODS: Data from patients with PsA across 13 European Spondyloarthritis Research Collaboration Network registries starting their first TNFi were pooled. Logistic regression was used to analyze the association between sex and treatment response using low disease activity (LDA) according to the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) (<3.2) at six months as the primary outcome. Analyses were adjusted for age, country, conventional synthetic disease-modifying antirheumatic drug treatment, and TNFi start year. Retention rates were explored using the Kaplan-Meier estimator. RESULTS: We analyzed the treatment response of 7,679 patients with PsA (50% women) with available data on LDA at six months. At baseline, women and men had similar characteristics, including mean DAS28-CRP (women vs men, 4.4 [SD 1.2] vs 4.2 [SD 1.2]), though patient-reported outcome measures were worse in women. At six months, 64% of women and 78% of men had LDA (relative risk [RR] 0.82; 95% confidence interval [CI] 0.80-0.84). This difference was similar after adjustment (RR 0.83; 95% CI 0.81-0.85). TNFi retention rates were evaluated in 17,842 patients with PsA. Women had significantly lower retention rates than men at all time points (women 79%, 64%, and 50% vs men 88%, 77%, and 64% at 6, 12, and 24 months, respectively). CONCLUSION: Despite comparable disease characteristics at baseline, women with PsA have reduced treatment response and retention rates to their first TNFi, highlighting the need to consider sex differences in PsA research and management.

Aarhus University Hospital Aarhus Denmark

Amsterdam University Medical Centers Amsterdam The Netherlands

Charles University Prague Czech Republic

Copenhagen Center for Arthritis Research Center for Rheumatology and Spine Diseases Centre for Head and Orthopedics Rigshospitalet Glostrup and Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

Copenhagen Center for Arthritis Research Center for Rheumatology and Spine Diseases Centre for Head and Orthopedics Rigshospitalet Glostrup Denmark

DANBIO and Copenhagen Center for Arthritis Research Center for Rheumatology and Spine Diseases Centre for Head and Orthopedics Rigshospitalet Glostrup University of Copenhagen Copenhagen Denmark

Diakonhjemmet Hospital Oslo and Sørlandet Hospital Kristiansand Norway

Diakonhjemmet Hospital Oslo Norway

Dokuz Eylul University School of Medicine Izmir Turkey

Geneva University Hospital Geneva Switzerland

Helsinki University Hospital and University of Helsinki Helsinki Finland

Hospital de Santa Maria Lisbon Portugal

Hospital Garcia de Orta Almada Portugal

Hospital General Universitario Gregorio Marañón Madrid Spain

Inselspital University Hospital Bern University of Bern Bern Switzerland

Institute of Rheumatology and Charles University Prague Czech Republic

Landspitali University Hospital and University of Iceland Reykjavik Iceland

Radboud University Medical Center Nijmegen The Netherlands

Sahlgrenska Academy at University of Gothenburg Gothenburg Sweden

Skåne University Hospital and Lund University Lund Sweden

Universidad de La Laguna La Laguna Spain

University Medical Centre Ljubljana and University of Ljubljana Ljubljana Slovenia

University Medical Centre Ljubljana Ljubljana Slovenia

University of Bari Bari Italy

University of Medicine and Pharmacy Bucharest Romania

University of Medicine Padova Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006622
003      
CZ-PrNML
005      
20240423155414.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/art.42758 $2 doi
035    __
$a (PubMed)37975166
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hellamand, Pasoon $u Amsterdam University Medical Centers, Amsterdam, The Netherlands $1 https://orcid.org/0000000222513435
245    10
$a Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network / $c P. Hellamand, MGH. van de Sande, LM. Ørnbjerg, T. Klausch, KK. Eklund, H. Relas, MJ. Santos, E. Vieira-Sousa, AG. Loft, B. Glintborg, M. Østergaard, U. Lindström, JK. Wallman, B. Michelsen, KM. Fagerli, I. Castrejón, B. Gudbjornsson, TJ. Love, J. Vencovský, L. Nekvindová, Ž. Rotar, M. Tomšič, F. Díaz-González, G. Kenar, HY. Tuğsal, F. Iannone, R. Ramonda, C. Codreanu, C. Mogosan, MJ. Nissen, B. Möller, ML. Hetland, IE. van der Horst-Bruinsma
520    9_
$a OBJECTIVE: Women with psoriatic arthritis (PsA) may have reduced tumor necrosis factor inhibitor (TNFi) effectiveness compared to men. We examined sex differences in treatment response and retention rates during 24 months of follow-up among patients with PsA initiating their first TNFi. METHODS: Data from patients with PsA across 13 European Spondyloarthritis Research Collaboration Network registries starting their first TNFi were pooled. Logistic regression was used to analyze the association between sex and treatment response using low disease activity (LDA) according to the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) (<3.2) at six months as the primary outcome. Analyses were adjusted for age, country, conventional synthetic disease-modifying antirheumatic drug treatment, and TNFi start year. Retention rates were explored using the Kaplan-Meier estimator. RESULTS: We analyzed the treatment response of 7,679 patients with PsA (50% women) with available data on LDA at six months. At baseline, women and men had similar characteristics, including mean DAS28-CRP (women vs men, 4.4 [SD 1.2] vs 4.2 [SD 1.2]), though patient-reported outcome measures were worse in women. At six months, 64% of women and 78% of men had LDA (relative risk [RR] 0.82; 95% confidence interval [CI] 0.80-0.84). This difference was similar after adjustment (RR 0.83; 95% CI 0.81-0.85). TNFi retention rates were evaluated in 17,842 patients with PsA. Women had significantly lower retention rates than men at all time points (women 79%, 64%, and 50% vs men 88%, 77%, and 64% at 6, 12, and 24 months, respectively). CONCLUSION: Despite comparable disease characteristics at baseline, women with PsA have reduced treatment response and retention rates to their first TNFi, highlighting the need to consider sex differences in PsA research and management.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    12
$a psoriatická artritida $x farmakoterapie $7 D015535
650    _2
$a inhibitory TNF $x terapeutické užití $7 D000079424
650    _2
$a pohlavní dimorfismus $7 D012727
650    _2
$a TNF-alfa $7 D014409
650    _2
$a výsledek terapie $7 D016896
650    12
$a antirevmatika $x terapeutické užití $7 D018501
650    12
$a spondylartritida $x farmakoterapie $7 D025241
655    _2
$a časopisecké články $7 D016428
700    1_
$a van de Sande, Marleen G H $u Amsterdam University Medical Centers, Amsterdam, The Netherlands
700    1_
$a Ørnbjerg, Lykke M $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, Denmark
700    1_
$a Klausch, Thomas $u Amsterdam University Medical Centers, Amsterdam, The Netherlands
700    1_
$a Eklund, Kari K $u Helsinki University Hospital and University of Helsinki, Helsinki, Finland
700    1_
$a Relas, Heikki $u Helsinki University Hospital and University of Helsinki, Helsinki, Finland
700    1_
$a Santos, Maria J $u Hospital Garcia de Orta, Almada, Portugal $1 https://orcid.org/0000000279461365
700    1_
$a Vieira-Sousa, Elsa $u Hospital de Santa Maria, Lisbon, Portugal
700    1_
$a Loft, Anne G $u Aarhus University Hospital, Aarhus, Denmark $1 https://orcid.org/000000016374841X
700    1_
$a Glintborg, Bente $u DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000289318482
700    1_
$a Østergaard, Mikkel $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Lindström, Ulf $u Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden $1 https://orcid.org/0000000222509348
700    1_
$a Wallman, Johan K $u Skåne University Hospital and Lund University, Lund, Sweden $1 https://orcid.org/0000000249152924
700    1_
$a Michelsen, Brigitte $u Diakonhjemmet Hospital, Oslo and Sørlandet Hospital, Kristiansand, Norway
700    1_
$a Fagerli, Karen M $u Diakonhjemmet Hospital, Oslo, Norway
700    1_
$a Castrejón, Isabel $u Hospital General, Universitario Gregorio Marañón, Madrid, Spain $1 https://orcid.org/0000000318112417
700    1_
$a Gudbjornsson, Bjorn $u Landspitali University Hospital and University of Iceland, Reykjavik, Iceland
700    1_
$a Love, Thorvardur J $u Landspitali University Hospital and University of Iceland, Reykjavik, Iceland
700    1_
$a Vencovský, Jiří $u Institute of Rheumatology and Charles University, Prague, Czech Republic
700    1_
$a Nekvindová, Lucie $u Charles University, Prague, Czech Republic
700    1_
$a Rotar, Žiga $u University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia
700    1_
$a Tomšič, Matija $u University Medical Centre Ljubljana, Ljubljana, Slovenia
700    1_
$a Díaz-González, Federico $u Universidad de La Laguna, La Laguna, Spain $1 https://orcid.org/0000000241399295
700    1_
$a Kenar, Gökçe $u Dokuz Eylul University School of Medicine, Izmir, Turkey $1 https://orcid.org/0000000204851369
700    1_
$a Tuğsal, Handan Y $u Dokuz Eylul University School of Medicine, Izmir, Turkey $1 https://orcid.org/000000030633790X
700    1_
$a Iannone, Florenzo $u University of Bari, Bari, Italy $1 https://orcid.org/0000000304745344
700    1_
$a Ramonda, Roberta $u University of Medicine, Padova, Italy $1 https://orcid.org/0000000296838873
700    1_
$a Codreanu, Catalin $u University of Medicine and Pharmacy, Bucharest, Romania
700    1_
$a Mogosan, Corina $u University of Medicine and Pharmacy, Bucharest, Romania
700    1_
$a Nissen, Michael J $u Geneva University Hospital, Geneva, Switzerland
700    1_
$a Möller, Burkhard $u Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland $1 https://orcid.org/0000000187696167
700    1_
$a Hetland, Merete L $u DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup, University of Copenhagen, Copenhagen, Denmark
700    1_
$a van der Horst-Bruinsma, Irene E $u Radboud University Medical Center, Nijmegen, The Netherlands $1 https://orcid.org/0000000280869915
773    0_
$w MED00188151 $t Arthritis & rheumatology $x 2326-5205 $g Roč. 76, č. 4 (2024), s. 587-598
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37975166 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155411 $b ABA008
999    __
$a ok $b bmc $g 2080934 $s 1216389
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 76 $c 4 $d 587-598 $e 20240225 $i 2326-5205 $m Arthritis & rheumatology $n Arthritis Rheumatol $x MED00188151
GRA    __
$p European Spondyloarthritis Research Collaboration Network
GRA    __
$p Novartis
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace